Stifel analyst Paul Matteis maintains $Neurogene (NGNE.US)$ with a buy rating, and maintains the target price at $46.
According to TipRanks data, the analyst has a success rate of 39.5% and a total average return of 2.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:
The valuation of Neurogene's shares is now closely aligned with its cash reserves following disclosures of a Serious Adverse Event in its NGN-401 high dose trial and the termination of the Battens program on November 11. Despite these setbacks, the company's management remains optimistic, not anticipating a clinical hold, as discussions with the FDA have suggested the safety of the low-dose option.
The firm revised its projections for third quarter 2024 earnings and incorporated the effects of a trial participant landing in critical condition following a high dose of NGN-401. This adjustment in analysis further influenced the expected market share for NGN-401 in the Rett syndrome gene therapy market, now estimated at 50%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析師Paul Matteis維持$Neurogene (NGNE.US)$買入評級，維持目標價46美元。
根據TipRanks數據顯示，該分析師近一年總勝率為39.5%，總平均回報率為2.2%。
此外，綜合報道，$Neurogene (NGNE.US)$近期主要分析師觀點如下：
Neurogene股票的估值現在與其現金儲備緊密對齊，因爲NGN-401高劑量試驗出現嚴重不良事件並於11月11日終止巴頓計劃的披露。儘管遇到這些挫折，公司管理層仍然樂觀，不預期會有臨床持有，在與FDA的討論中表明低劑量選擇的安全性。
該公司修訂了2024年第三季度收益預測，並納入了一名試驗參與者因NGN-401高劑量導致重症的影響。這一分析調整進一步影響了Rett綜合症基因治療市場中NGN-401的預期市場份額，目前估計爲50%。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
